Xconomy National

Archives

by in

Entry	Author	Date	Location
Onyx Drug Effective in New Myeloma Patients, Taking Aim at Millennium	Luke Timmerman	12/12/11	San Francisco
Epigenetic Drug Startup Tensha Therapeutics Snags $15M Series A	Erin Kutz	09/12/11	Boston
Seattle Genetics: The Next Litmus Test for High Priced Cancer Drugs	Luke Timmerman	08/22/11	National
Xconomist of the Week: Tony Coles’ Journey from Mass General Doctor to SF Biotech CEO	Luke Timmerman	08/18/11	National
Onyx Unveils Results for Myeloma Drug, Raising Stakes in Rivalry with Millennium	Luke Timmerman	12/07/10	San Francisco
Glaxo Ends Resveratrol Drug Study	Ryan McBride	12/01/10	Boston
Onyx Delays Cancer Drug Application as FDA Asks for More Data on Manufacturing	Luke Timmerman	10/07/10	San Francisco
Onyx Pockets $59M Upfront From Japanese Partner, to Market Myeloma Drugs	Luke Timmerman	09/08/10	San Francisco
LS9 Reveals Key Biofuel Genes, Onyx Drug Passes Big Trial, Solazyme Seeks First-Mover Edge, & More Bay Area Life Sciences News	Luke Timmerman	07/30/10	San Francisco
Onyx Preps for Dash to FDA, After Myeloma Drug Helps Sickest of the Sick	Luke Timmerman	07/26/10	San Francisco
Oncothyreon Stock Plummets as Side Effect Emerges in Cancer Patient, Trials Halted	Luke Timmerman	03/23/10	Seattle
Roche Scraps Partnership With Seattle Genetics on Lymphoma Drug	Luke Timmerman	12/11/09	Seattle
How Millennium Is Tapping A Harvard Lab to Help Discover New Cancer Drugs	Ryan McBride	11/24/09	Boston
Acceleron, Bucking Conventional Wisdom, Pushes Ahead Drug For Bone Loss, Anemia	Luke Timmerman	09/11/09	Boston
$252M Potential in CLDA and CombinatoRx Deal	Ryan McBride	08/13/09	Boston
Biotech Startup Acetylon Pharma Catches $7.25M in A Round from Backers Such As New England Patriots Owner	Ryan McBride	08/07/09	Boston
Genzyme’s Mozobil Gets European Approval	Ryan McBride	08/05/09	Boston
Genzyme Wins FDA Approval of Mozobil	Luke Timmerman	12/15/08	Boston
Blood News: A Quick Rundown of Headlines From the American Society of Hematology	Luke Timmerman	12/09/08	National
Millennium’s Velcade, As Time Wears On, Shows Durable Ability to Prolong Lives	Luke Timmerman	12/08/08	Boston
Biogen Turns Down Dying Patient’s Request For Tysabri—and Explains Why	Luke Timmerman	10/14/08	Boston
Biogen Idec, Elan Start First Cancer Trial With Tysabri	Luke Timmerman	09/05/08	Boston
Page 1 of 1